---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-096510"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-08-14T12:36:29+00:00"
generated_at: "2026-08-14T12:40:06.576068+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics raises ~$55M in public offering of common stock and warrants

## Summary
- 55,555,556 shares and warrants sold at $0.99 combined; gross proceeds ~$55M.
- Warrants exercisable at $1.10/share, expire in 5 years; underwriters' option for 8.33M additional warrants exercised.
- GMS Ventures (largest stockholder) bought 2,525,252 shares; CEO Robert Jahr and CFO Lawrence Kenyon bought 151,515 and 101,010 shares respectively.
- Offering expected to close Aug 14, 2026; Piper Sandler and BTIG are underwriters.

## SEC filing metadata
- accession: 0001104659-26-096510
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-08-14T12:36:29+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926096510/0001104659-26-096510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926096510/tm2622399d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-096510
- JSON: https://secwatch.observer/filing/0001104659-26-096510.json
- Plain text: https://secwatch.observer/filing/0001104659-26-096510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.